Horizon Pharma's (HZNP) FY16 Revenue Guidance Tops Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Actimmune and Friedreich's Ataxia Could Help Horizon Pharma (HZNP) Post Upside, Mizuho Says; PT to $34
November 10, 2015 6:57 AM ESTHorizon Pharma (NASDAQ: HZNP) reported 3Q:15 revenue of $226.5M vs. consensus of $193.2M. Adjusted EPS of $0.70 also beat the consensus number of $0.41. The beat was driven by strong product demand (volumes) across all of the company's brands, coupled with lower than expected SG&A expense and... More
